S&P 500   3,678.43 (+2.59%)
DOW   29,490.89 (+2.66%)
QQQ   274.28 (+2.63%)
AAPL   142.72 (+3.27%)
MSFT   241.35 (+3.63%)
META   138.91 (+2.38%)
GOOGL   98.92 (+3.42%)
AMZN   116.33 (+2.95%)
TSLA   242.61 (-8.54%)
NVDA   125.33 (+3.25%)
NIO   15.53 (-1.52%)
BABA   80.67 (+0.85%)
AMD   66.28 (+4.61%)
T   15.90 (+3.65%)
MU   51.73 (+3.25%)
CGC   2.90 (+6.23%)
F   11.47 (+2.41%)
GE   63.59 (+2.71%)
DIS   97.11 (+2.95%)
AMC   6.81 (-2.30%)
PYPL   87.29 (+1.42%)
PFE   44.19 (+0.98%)
NFLX   239.36 (+1.66%)
S&P 500   3,678.43 (+2.59%)
DOW   29,490.89 (+2.66%)
QQQ   274.28 (+2.63%)
AAPL   142.72 (+3.27%)
MSFT   241.35 (+3.63%)
META   138.91 (+2.38%)
GOOGL   98.92 (+3.42%)
AMZN   116.33 (+2.95%)
TSLA   242.61 (-8.54%)
NVDA   125.33 (+3.25%)
NIO   15.53 (-1.52%)
BABA   80.67 (+0.85%)
AMD   66.28 (+4.61%)
T   15.90 (+3.65%)
MU   51.73 (+3.25%)
CGC   2.90 (+6.23%)
F   11.47 (+2.41%)
GE   63.59 (+2.71%)
DIS   97.11 (+2.95%)
AMC   6.81 (-2.30%)
PYPL   87.29 (+1.42%)
PFE   44.19 (+0.98%)
NFLX   239.36 (+1.66%)
S&P 500   3,678.43 (+2.59%)
DOW   29,490.89 (+2.66%)
QQQ   274.28 (+2.63%)
AAPL   142.72 (+3.27%)
MSFT   241.35 (+3.63%)
META   138.91 (+2.38%)
GOOGL   98.92 (+3.42%)
AMZN   116.33 (+2.95%)
TSLA   242.61 (-8.54%)
NVDA   125.33 (+3.25%)
NIO   15.53 (-1.52%)
BABA   80.67 (+0.85%)
AMD   66.28 (+4.61%)
T   15.90 (+3.65%)
MU   51.73 (+3.25%)
CGC   2.90 (+6.23%)
F   11.47 (+2.41%)
GE   63.59 (+2.71%)
DIS   97.11 (+2.95%)
AMC   6.81 (-2.30%)
PYPL   87.29 (+1.42%)
PFE   44.19 (+0.98%)
NFLX   239.36 (+1.66%)
S&P 500   3,678.43 (+2.59%)
DOW   29,490.89 (+2.66%)
QQQ   274.28 (+2.63%)
AAPL   142.72 (+3.27%)
MSFT   241.35 (+3.63%)
META   138.91 (+2.38%)
GOOGL   98.92 (+3.42%)
AMZN   116.33 (+2.95%)
TSLA   242.61 (-8.54%)
NVDA   125.33 (+3.25%)
NIO   15.53 (-1.52%)
BABA   80.67 (+0.85%)
AMD   66.28 (+4.61%)
T   15.90 (+3.65%)
MU   51.73 (+3.25%)
CGC   2.90 (+6.23%)
F   11.47 (+2.41%)
GE   63.59 (+2.71%)
DIS   97.11 (+2.95%)
AMC   6.81 (-2.30%)
PYPL   87.29 (+1.42%)
PFE   44.19 (+0.98%)
NFLX   239.36 (+1.66%)
NASDAQ:DVAX

Dynavax Technologies - DVAX Stock Forecast, Price & News

$10.80
+0.36 (+3.45%)
(As of 10/3/2022 03:59 PM ET)
Add
Compare
Today's Range
$10.43
$11.04
50-Day Range
$9.93
$17.44
52-Week Range
$7.26
$21.39
Volume
94,378 shs
Average Volume
2.26 million shs
Market Capitalization
$1.37 billion
P/E Ratio
7.71
Dividend Yield
N/A
Price Target
$25.00

Dynavax Technologies MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
130.6% Upside
$25.00 Price Target
Short Interest
Bearish
12.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
0.98mentions of Dynavax Technologies in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.09 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From $1.73 to ($0.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

292nd out of 1,093 stocks

Pharmaceutical Preparations Industry

127th out of 548 stocks

DVAX stock logo

About Dynavax Technologies (NASDAQ:DVAX) Stock

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

DVAX Stock News Headlines

Dynavax Technologies (NASDAQ: DVAX)
Dynavax Technologies (NASDAQ:DVAX) Now Covered by JMP Securities
Why Dynavax Stock Popped by Over 5% Today
Is Dynavax Technologies (DVAX) Stock Undervalued Right Now?
Dynavax Technologies: Q2 Earnings Insights
Why Dynavax Stock Was Crushing It on Friday
Dynavax Reports Second Quarter 2022 Financial Results
See More Headlines
Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

DVAX Company Calendar

Last Earnings
8/04/2022
Today
10/03/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:DVAX
CUSIP
26815810
Employees
311
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$25.00
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+131.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
2 Analysts

Profitability

Net Income
$76.71 million
Pretax Margin
34.79%

Debt

Sales & Book Value

Annual Sales
$439.44 million
Cash Flow
$1.03 per share
Book Value
$1.85 per share

Miscellaneous

Free Float
114,699,000
Market Cap
$1.37 billion
Optionable
Optionable
Beta
1.32

Social Links


Key Executives

  • Mr. Ryan SpencerMr. Ryan Spencer (Age 44)
    CEO & Director
    Comp: $1.19M
  • Mr. David F. NovackMr. David F. Novack (Age 60)
    Pres & COO
    Comp: $969.98k
  • Ms. Kelly MacDonaldMs. Kelly MacDonald (Age 38)
    Sr. VP & CFO
    Comp: $553.42k
  • Mr. Michael S. Ostrach (Age 70)
    Advisor
    Comp: $728.34k
  • Dr. Robert JanssenDr. Robert Janssen (Age 68)
    Chief Medical Officer and Sr. VP of Clinical Devel., Medical & Regulatory Affairs
    Comp: $817.17k
  • Mr. Justin BurgessMr. Justin Burgess
    Principal Accounting Officer & Controller
  • Mr. Jeff P. Coon (Age 59)
    CHRO and Sr. VP of HR & Admin.
  • Nicole Arndt
    Sr. Mang. of Investor Relations
  • Mr. John Slebir
    Sr. VP & Gen. Counsel
  • Ms. Meg Smith
    VP Sales & Operations













DVAX Stock - Frequently Asked Questions

Should I buy or sell Dynavax Technologies stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DVAX shares.
View DVAX analyst ratings
or view top-rated stocks.

What is Dynavax Technologies' stock price forecast for 2022?

2 analysts have issued 1-year target prices for Dynavax Technologies' stock. Their DVAX share price forecasts range from $22.00 to $28.00. On average, they predict the company's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 127.9% from the stock's current price.
View analysts price targets for DVAX
or view top-rated stocks among Wall Street analysts.

How have DVAX shares performed in 2022?

Dynavax Technologies' stock was trading at $14.07 at the beginning of 2022. Since then, DVAX shares have decreased by 22.0% and is now trading at $10.97.
View the best growth stocks for 2022 here
.

When is Dynavax Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our DVAX earnings forecast
.

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) issued its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.22 by $0.64. The biopharmaceutical company earned $256.46 million during the quarter, compared to analyst estimates of $147.57 million. Dynavax Technologies had a trailing twelve-month return on equity of 107.10% and a net margin of 34.58%.

What is Eddie Gray's approval rating as Dynavax Technologies' CEO?

13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

How do I buy shares of Dynavax Technologies?

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $10.97.

How much money does Dynavax Technologies make?

Dynavax Technologies (NASDAQ:DVAX) has a market capitalization of $1.39 billion and generates $439.44 million in revenue each year. The biopharmaceutical company earns $76.71 million in net income (profit) each year or $1.40 on an earnings per share basis.

How many employees does Dynavax Technologies have?

The company employs 311 workers across the globe.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The official website for the company is www.dynavax.com. The biopharmaceutical company can be reached via phone at (510) 848-5100, via email at ir@dynavax.com, or via fax at 510-848-1327.

This page (NASDAQ:DVAX) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.